看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | -0.9x - -1.0x | -1.0x |
| Selected Fwd EBIT Multiple | -0.1x - -0.1x | -0.1x |
| Fair Value | $3.56 - $3.86 | $3.71 |
| Upside | 18.6% - 28.7% | 23.7% |
| Benchmarks | Ticker | Full Ticker |
| Exact Sciences Corporation | EXAS | NasdaqCM:EXAS |
| Generation Bio Co. | GBIO | NasdaqGS:GBIO |
| Precigen, Inc. | PGEN | NasdaqGS:PGEN |
| Curis, Inc. | CRIS | NasdaqCM:CRIS |
| MaxCyte, Inc. | MXCT | NasdaqGS:MXCT |
| Alaunos Therapeutics, Inc. | TCRT | NasdaqCM:TCRT |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| EXAS | GBIO | PGEN | CRIS | MXCT | TCRT | ||
| NasdaqCM:EXAS | NasdaqGS:GBIO | NasdaqGS:PGEN | NasdaqCM:CRIS | NasdaqGS:MXCT | NasdaqCM:TCRT | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| Latest Twelve Months | 32.1% | 42.8% | -6.5% | 7.8% | -6.0% | 83.1% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | -25.6% | -3613.3% | -776.4% | -398.4% | -73.3% | -109924.7% | |
| Prior Fiscal Year | -10.9% | -2346.9% | -1428.5% | -482.2% | -117.0% | -569860.0% | |
| Latest Fiscal Year | -6.7% | -398.1% | -2412.9% | -408.3% | -132.5% | -48120.0% | |
| Latest Twelve Months | -6.7% | -398.1% | -2412.9% | -408.3% | -132.5% | -48120.0% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 3.49x | -3.34x | 69.35x | 2.53x | 2.22x | 363.27x | |
| EV / LTM EBITDA | 324.0x | 0.9x | -3.0x | -0.6x | -1.8x | -0.8x | |
| EV / LTM EBIT | -52.1x | 0.8x | -2.9x | -0.6x | -1.7x | -0.8x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -52.1x | -1.7x | 0.8x | ||||
| Historical EV / LTM EBIT | -5.5x | -2.0x | -0.2x | ||||
| Selected EV / LTM EBIT | -0.9x | -1.0x | -1.0x | ||||
| (x) LTM EBIT | (5) | (5) | (5) | ||||
| (=) Implied Enterprise Value | 4 | 5 | 5 | ||||
| (-) Non-shareholder Claims * | 1 | 1 | 1 | ||||
| (=) Equity Value | 6 | 6 | 6 | ||||
| (/) Shares Outstanding | 1.6 | 1.6 | 1.6 | ||||
| Implied Value Range | 3.49 | 3.64 | 3.79 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 3.49 | 3.64 | 3.79 | 3.00 | |||
| Upside / (Downside) | 16.4% | 21.3% | 26.2% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | EXAS | GBIO | PGEN | CRIS | MXCT | TCRT | |
| Enterprise Value | 9,821 | (67) | 299 | 27 | 90 | 4 | |
| (+) Cash & Short Term Investments | 1,038 | 185 | 98 | 20 | 154 | 1 | |
| (+) Investments & Other | 58 | 0 | 0 | 0 | 36 | 0 | |
| (-) Debt | (2,776) | (94) | (6) | (37) | (18) | 0 | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 8,142 | 25 | 391 | 10 | 263 | 5 | |
| (/) Shares Outstanding | 185.8 | 67.0 | 294.0 | 8.5 | 106.3 | 1.6 | |
| Implied Stock Price | 43.83 | 0.38 | 1.33 | 1.16 | 2.47 | 3.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 43.83 | 0.38 | 1.33 | 1.16 | 2.47 | 3.00 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |